Sublingual immunotherapy for allergic rhinitis

An update

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The inter-relationship between allergy and nasal diseases has long been known. Failure to address when allergy is a contributing factor diminishes the possibility of a successful surgical intervention. Sublingual immunotherapy is recommended by the World Health Organization to treat allergic rhinitis and is widely used in Europe. Many clinical trials and rigorous meta-analysis support its efficacy. The criteria, however, for the integration of this treatment (with the surgical management of those allergic patients who suffer chronic nasal obstruction, severe drug-resistant hypertrophy and increase in glandular structures of the inferior turbinates) are not fully established. We review here the most recent literature on the efficacy and safety of sublingual immunotherapy. The purpose is to stimulate the use of complementary approaches by ear, nose and throat doctors and allergologists, and to improve the management of patients with persistent allergic rhinitis. RECENT FINDINGS: In addition to the results of clinical trials, postmarketing surveillance has confirmed the high safety profile of sublingual immunotherapy in adults and children, its positive impact on the quality of life, and the reduction of the personal and social cost of allergy. Sublingual immunotherapy can prevent new allergic sensitizations and maintain its beneficial effect for years after its discontinuation. SUMMARY: Sublingual immunotherapy is a highly efficacious and well tolerated form of immunotherapy for allergic rhinitis, and it is capable of interfering with disease progression. Sublingual immunotherapy should be integrated with surgical intervention to achieve optimal outcomes in allergic subjects with chronic nasal obstruction.

Original languageEnglish
Pages (from-to)197-201
Number of pages5
JournalCurrent Opinion in Otolaryngology and Head and Neck Surgery
Volume14
Issue number3
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Sublingual Immunotherapy
Hypersensitivity
Nasal Obstruction
Clinical Trials
Nose Diseases
Safety
Turbinates
Pharynx
Nose
Immunotherapy
Hypertrophy
Ear
Disease Progression
Meta-Analysis
Allergic Rhinitis
Quality of Life
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • Allergic rhinitis
  • Efficacy
  • Safety
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Sublingual immunotherapy for allergic rhinitis : An update. / Burastero, Samuele E.

In: Current Opinion in Otolaryngology and Head and Neck Surgery, Vol. 14, No. 3, 06.2006, p. 197-201.

Research output: Contribution to journalArticle

@article{840b3cdb54b34126b34ca34b6ece1971,
title = "Sublingual immunotherapy for allergic rhinitis: An update",
abstract = "PURPOSE OF REVIEW: The inter-relationship between allergy and nasal diseases has long been known. Failure to address when allergy is a contributing factor diminishes the possibility of a successful surgical intervention. Sublingual immunotherapy is recommended by the World Health Organization to treat allergic rhinitis and is widely used in Europe. Many clinical trials and rigorous meta-analysis support its efficacy. The criteria, however, for the integration of this treatment (with the surgical management of those allergic patients who suffer chronic nasal obstruction, severe drug-resistant hypertrophy and increase in glandular structures of the inferior turbinates) are not fully established. We review here the most recent literature on the efficacy and safety of sublingual immunotherapy. The purpose is to stimulate the use of complementary approaches by ear, nose and throat doctors and allergologists, and to improve the management of patients with persistent allergic rhinitis. RECENT FINDINGS: In addition to the results of clinical trials, postmarketing surveillance has confirmed the high safety profile of sublingual immunotherapy in adults and children, its positive impact on the quality of life, and the reduction of the personal and social cost of allergy. Sublingual immunotherapy can prevent new allergic sensitizations and maintain its beneficial effect for years after its discontinuation. SUMMARY: Sublingual immunotherapy is a highly efficacious and well tolerated form of immunotherapy for allergic rhinitis, and it is capable of interfering with disease progression. Sublingual immunotherapy should be integrated with surgical intervention to achieve optimal outcomes in allergic subjects with chronic nasal obstruction.",
keywords = "Allergic rhinitis, Efficacy, Safety, Sublingual immunotherapy",
author = "Burastero, {Samuele E.}",
year = "2006",
month = "6",
doi = "10.1097/01.moo.0000193187.23063.ae",
language = "English",
volume = "14",
pages = "197--201",
journal = "Current Opinion in Otolaryngology and Head and Neck Surgery",
issn = "1068-9508",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Sublingual immunotherapy for allergic rhinitis

T2 - An update

AU - Burastero, Samuele E.

PY - 2006/6

Y1 - 2006/6

N2 - PURPOSE OF REVIEW: The inter-relationship between allergy and nasal diseases has long been known. Failure to address when allergy is a contributing factor diminishes the possibility of a successful surgical intervention. Sublingual immunotherapy is recommended by the World Health Organization to treat allergic rhinitis and is widely used in Europe. Many clinical trials and rigorous meta-analysis support its efficacy. The criteria, however, for the integration of this treatment (with the surgical management of those allergic patients who suffer chronic nasal obstruction, severe drug-resistant hypertrophy and increase in glandular structures of the inferior turbinates) are not fully established. We review here the most recent literature on the efficacy and safety of sublingual immunotherapy. The purpose is to stimulate the use of complementary approaches by ear, nose and throat doctors and allergologists, and to improve the management of patients with persistent allergic rhinitis. RECENT FINDINGS: In addition to the results of clinical trials, postmarketing surveillance has confirmed the high safety profile of sublingual immunotherapy in adults and children, its positive impact on the quality of life, and the reduction of the personal and social cost of allergy. Sublingual immunotherapy can prevent new allergic sensitizations and maintain its beneficial effect for years after its discontinuation. SUMMARY: Sublingual immunotherapy is a highly efficacious and well tolerated form of immunotherapy for allergic rhinitis, and it is capable of interfering with disease progression. Sublingual immunotherapy should be integrated with surgical intervention to achieve optimal outcomes in allergic subjects with chronic nasal obstruction.

AB - PURPOSE OF REVIEW: The inter-relationship between allergy and nasal diseases has long been known. Failure to address when allergy is a contributing factor diminishes the possibility of a successful surgical intervention. Sublingual immunotherapy is recommended by the World Health Organization to treat allergic rhinitis and is widely used in Europe. Many clinical trials and rigorous meta-analysis support its efficacy. The criteria, however, for the integration of this treatment (with the surgical management of those allergic patients who suffer chronic nasal obstruction, severe drug-resistant hypertrophy and increase in glandular structures of the inferior turbinates) are not fully established. We review here the most recent literature on the efficacy and safety of sublingual immunotherapy. The purpose is to stimulate the use of complementary approaches by ear, nose and throat doctors and allergologists, and to improve the management of patients with persistent allergic rhinitis. RECENT FINDINGS: In addition to the results of clinical trials, postmarketing surveillance has confirmed the high safety profile of sublingual immunotherapy in adults and children, its positive impact on the quality of life, and the reduction of the personal and social cost of allergy. Sublingual immunotherapy can prevent new allergic sensitizations and maintain its beneficial effect for years after its discontinuation. SUMMARY: Sublingual immunotherapy is a highly efficacious and well tolerated form of immunotherapy for allergic rhinitis, and it is capable of interfering with disease progression. Sublingual immunotherapy should be integrated with surgical intervention to achieve optimal outcomes in allergic subjects with chronic nasal obstruction.

KW - Allergic rhinitis

KW - Efficacy

KW - Safety

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33744952208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744952208&partnerID=8YFLogxK

U2 - 10.1097/01.moo.0000193187.23063.ae

DO - 10.1097/01.moo.0000193187.23063.ae

M3 - Article

VL - 14

SP - 197

EP - 201

JO - Current Opinion in Otolaryngology and Head and Neck Surgery

JF - Current Opinion in Otolaryngology and Head and Neck Surgery

SN - 1068-9508

IS - 3

ER -